Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6WRH

The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant

Summary for 6WRH
Entry DOI10.2210/pdb6wrh/pdb
Related6W9C
DescriptorNon-structural protein 3, ZINC ION, PHOSPHATE ION, ... (6 entities in total)
Functional Keywordscovid-19, coronavirus, sars, cov-2, papain-like protease, idp51000, center for structural genomics of infectious diseases, csgid, hydrolase
Biological sourceSevere acute respiratory syndrome coronavirus 2 (2019-nCoV)
Total number of polymer chains1
Total formula weight36533.11
Authors
Primary citationOsipiuk, J.,Azizi, S.A.,Dvorkin, S.,Endres, M.,Jedrzejczak, R.,Jones, K.A.,Kang, S.,Kathayat, R.S.,Kim, Y.,Lisnyak, V.G.,Maki, S.L.,Nicolaescu, V.,Taylor, C.A.,Tesar, C.,Zhang, Y.A.,Zhou, Z.,Randall, G.,Michalska, K.,Snyder, S.A.,Dickinson, B.C.,Joachimiak, A.
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.
Nat Commun, 12:743-743, 2021
Cited by
PubMed Abstract: The pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to expand. Papain-like protease (PLpro) is one of two SARS-CoV-2 proteases potentially targetable with antivirals. PLpro is an attractive target because it plays an essential role in cleavage and maturation of viral polyproteins, assembly of the replicase-transcriptase complex, and disruption of host responses. We report a substantive body of structural, biochemical, and virus replication studies that identify several inhibitors of the SARS-CoV-2 enzyme. We determined the high resolution structure of wild-type PLpro, the active site C111S mutant, and their complexes with inhibitors. This collection of structures details inhibitors recognition and interactions providing fundamental molecular and mechanistic insight into PLpro. All compounds inhibit the peptidase activity of PLpro in vitro, some block SARS-CoV-2 replication in cell culture assays. These findings will accelerate structure-based drug design efforts targeting PLpro to identify high-affinity inhibitors of clinical value.
PubMed: 33531496
DOI: 10.1038/s41467-021-21060-3
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.6 Å)
Structure validation

229183

PDB entries from 2024-12-18

PDB statisticsPDBj update infoContact PDBjnumon